Editas Medicine Inc (EDIT NASDAQ) stock market data APIs
$2.4809
0.11(4.4%)
as of November 7, 2025
Try our APIs with
free plan!
Editas Medicine Inc Financial Data Overview
Price chart is built with
Anychart
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Prev. Close
2.4809
Open
2.5937
High
2.5937
Low
2.3511
52 wk Range
0.9101-4.5372
Market Cap
222 M
Shares Outstanding
89 920 K
Revenue
38 901 K
EPS
0
Beta
2.423
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Editas Medicine Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Editas Medicine Inc data using free add-ons & libraries
Get Editas Medicine Inc Fundamental Data
Editas Medicine Inc Fundamental data includes:
- Net Revenue: 38 901 K
- EBITDA: -154 068 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-10
- EPS/Forecast: -0.2961
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Editas Medicine Inc News
New
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.51 per share a year ago. These fi...
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $2.47 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.02 per share a year ago. These figu...
After-Hours Rally Lifts PALI, HCTI, NTRB, KPTI, EDIT, And CGON On Mixed News And Strategic Moves
(RTTNews) - Several biotech stocks posted notable after-hours gains on Thursday, October 9, driven by fresh data, strategic updates, and corporate developments. Here's a quick look at the key movers a...
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
CAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today reported in vivo preclinical proof-of-concept data for EDIT-401, ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
